Evidence map›Paper›PMID 40625564›Full record

ArticleSmart molecules : open access2025

A COVID-19 rapid antigen test employing upconversion nanoparticles.

Le Zhang, Jiajia Zhou, Olga Shimoni, Shihui Wen, Amani Alghalayini, Yuan Liu, Meysam Rezaeishahmirzadi, Jiayan Liao, Mahnaz Maddahfar, Roger Hunt and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Smart molecules : open access, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Le ZhangThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.ORCID https://orcid.org/0000-0003-0641-2383
Jiajia ZhouThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Olga ShimoniThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Shihui WenThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Amani AlghalayiniThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Yuan LiuThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Meysam RezaeishahmirzadiThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Jiayan LiaoThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Mahnaz MaddahfarFaculty of Science Institute for Biomedical Materials and Devices (IBMD) University of Technology Sydney Sydney New South Wales Australia.
Roger HuntThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Murdo BlackThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Matt D JohansenCentenary Institute Centre for Inflammation University of Technology Sydney Sydney New South Wales Australia.
Phil M HansbroCentenary Institute Centre for Inflammation University of Technology Sydney Sydney New South Wales Australia.
Lin ZhangCluster for Advanced Macromolecular Design (CAMD) School of Chemistry University of New South Wales Sydney New South Wales Australia.
Martina StenzelCluster for Advanced Macromolecular Design (CAMD) School of Chemistry University of New South Wales Sydney New South Wales Australia.
Majid WarkianiFaculty of Science Institute for Biomedical Materials and Devices (IBMD) University of Technology Sydney Sydney New South Wales Australia.
Stella M ValenzuelaThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.
Dayong JinThe ARC Research Hub for Integrated Devices for End-User Analysis at Low Levels (IDEAL) University of Technology Sydney Sydney New South Wales Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has underscored the critical need for rapid and accurate diagnostic tools. Current methods, including Polymerase Chain Reaction and rapid antigen tests (RAT), have limitations in speed, sensitivity, and the requirement for specialized equipment and trained personnel. Nanotechnology, particularly upconversion nanoparticles (UCNPs), offer a promising alternative due to their unique optical properties. UCNPs can convert low-energy near-infrared light into higher-energy visible light, making them ideal for use as optical probes in single molecule detection and point of care applications. This study, initiated in early 2020, explores the opportunity of using highly doped UCNPs (40%Yb

Indexed as

analytical methodsbiosensorluminescencetrace analysis

Identifiers

PMID40625564
PMCPMC12117886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.